Zimmerman Mark, Posternak Michael A, Chelminski Iwona
Department of Psychiatry and Human Behavior, Brown University School of Medicine, Rhode Island Hospital, Providence, Rhode Island, USA.
Int Clin Psychopharmacol. 2004 Jul;19(4):215-20. doi: 10.1097/01.yic.0000130232.57629.46.
A fundamental question in the medical management of disease is how well treatment works. Although there are many ways of defining improvement, one endpoint of definite interest is the resolution or remission of the disorder. In short-term antidepressant treatment trials, remission is usually defined according to post-treatment scores on symptom severity measures, such as the Hamilton Rating Scale for Depression (HRSD) or the Montgomery-Asberg Depression Rating Scale (MADRS). However, there is uncertainty as to what cut-offs should be used on these measures to define remission. During the past 2 years, as part of the Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) project, our laboratory has examined the question of how to define remission on the HRSD and MADRS. In the present report from the MIDAS project, we examined the impact of the cut-off score used to define remission on the percentage of depressed outpatients in ongoing treatment who are considered to be in remission. In addition, we examined the association between remission status and psychosocial impairment for different cut-off scores. Three hundred and three depressed psychiatric outpatients were rated on the MADRS, 17-item HRSD, and an index of DSM-IV remission status. Approximately one-third of patients completed a measure of psychosocial impairment. For both the HRSD and the MADRS, we examined four cut-off scores for remission. For each cut-off, we determined the percentage of patients who met the definition of remission, the percentage of patients who continued to meet DSM-IV criteria for major depressive disorder (MDD), and the percentage of patients without any self-reported impairment from depression. For both scales, the range of cut-off scores was associated with more than a two-fold difference in prevalence of remission. Based on higher thresholds to define remission, a small percentage of patients met criteria for MDD, whereas no patients scoring below the low thresholds had MDD. The threshold to define remission was associated with psychosocial impairment: higher cut-off scores were associated with lower rates of no impairment. The cut-offs used to define remission from depression considerably influence the percentage of patients considered to be in remission. Lower cut-off scores than those most commonly used to define remission appear to be more valid.
疾病医疗管理中的一个基本问题是治疗效果如何。尽管有多种定义改善情况的方法,但一个明确令人关注的终点是疾病的缓解或减轻。在短期抗抑郁治疗试验中,缓解通常根据治疗后症状严重程度量表的得分来定义,比如汉密尔顿抑郁量表(HRSD)或蒙哥马利-阿斯伯格抑郁量表(MADRS)。然而,对于这些量表应使用何种临界值来定义缓解存在不确定性。在过去两年里,作为罗德岛改善诊断评估与服务方法(MIDAS)项目的一部分,我们实验室研究了如何在HRSD和MADRS上定义缓解的问题。在这份来自MIDAS项目的报告中,我们研究了用于定义缓解的临界值对正在接受治疗的抑郁症门诊患者中被认为处于缓解状态的百分比的影响。此外,我们还研究了不同临界值下缓解状态与社会心理损害之间的关联。对303名抑郁症门诊患者进行了MADRS、17项HRSD评分以及DSM-IV缓解状态指标评估。约三分之一的患者完成了一项社会心理损害测量。对于HRSD和MADRS,我们都研究了四个缓解临界值。对于每个临界值,我们确定了符合缓解定义的患者百分比、继续符合DSM-IV重度抑郁症(MDD)标准的患者百分比以及没有任何自我报告的抑郁相关损害的患者百分比。对于这两个量表,临界值范围与缓解患病率的两倍多差异相关。基于更高的缓解定义阈值,一小部分患者符合MDD标准,而得分低于低阈值的患者中没有符合MDD标准的。定义缓解的阈值与社会心理损害相关:较高的临界值与无损害率较低相关。用于定义抑郁症缓解的临界值对被认为处于缓解状态的患者百分比有很大影响。比最常用于定义缓解的临界值更低的临界值似乎更有效。